Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer Science and Business Media Deutschland GmbH
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: The effect of preadmission metformin usage (PMU) on the mortality of coronavirus disease-2019 (COVID-19) patients with diabetes is conflicting. Most studies have focused on in-hospital mortality; however, mortality after discharge also increases in COVID-19 patients. Aims: Examining the effect of PMU on all-cause mortality, including the post-discharge period. Methods: Patients with diabetes who were hospitalised in 2020 due to COVID-19 were included in the study. They were divided into two groups: those with a history of metformin use (MF(+)) and those without such history (MF(−)). Propensity score matching (PSM) was performed at a ratio of 1:1 for age and sex. COX regression analyses were used to demonstrate risk factors for mortality. Results: We investigated 4103 patients hospitalised for COVID-19. After excluding those without diabetes or with chronic liver/kidney disease, we included the remaining 586 patients, constituting 293 women (50%) with an overall mean age of 66 ± 11.9 years. After PSM analysis, the in-hospital and post-discharge mortality rates were higher in the MF(−) group though not significantly different. However, overall mortality was higher in the MF(−) group (51 (42.5%) vs. 35 (29.2%), p = 0.031). For overall mortality, the adjusted HR was 0.585 (95% CI: 0.371 − 0.920, p = 0.020) in the MF(+) group. Conclusion: PMU is associated with reducing all-cause mortality. This effect starts from the in-hospital period and becomes more significant with the post-discharge period. The main limitations were the inability to evaluate the compliance with metformin and the effects of other medications due to retrospective nature.
Açıklama
Anahtar Kelimeler
Coronavirus disease 2019, Metformin, Mortality, Preadmission, Treatment
Kaynak
Irish Journal of Medical Science
WoS Q Değeri
Q3
Scopus Q Değeri
Cilt
191
Sayı
2
Künye
Saygili, E. S., Karakiliç, E., Mert, E., Şener, A., & Mirci, A. (2022). Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period. Irish Journal of Medical Science, 191(2), 569-575. doi:10.1007/s11845-021-02823-9
